Detalles de la búsqueda
1.
Lifetime Clinical Events Avoided And Resource Utilization With Apixaban Compared To Low-Molecular-Weight Heparin Followed By A Vitamin K Antagonist For The Treatment And Prevention Of Venous Thromboembolism.
Value Health
; 17(7): A475, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27201370
2.
Cost-Effectiveness Of Apixaban Compared To Other Anticoagulants For Lifetime Treatment And Prevention Of Recurrent Venous Thromboembolism.
Value Health
; 17(7): A488, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27201443
3.
Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism.
J Med Econ
; 20(1): 98-106, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27822962
4.
The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland.
Int J STD AIDS
; 27(1): 51-7, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25681263
5.
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
J Med Econ
; 17(8): 587-98, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24831811
6.
The cost of managing genital warts in the UK.
Int J STD AIDS
; 23(3): 189-94, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22581873
Resultados
1 -
6
de 6
1
Próxima >
>>